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Summary
Precise modeling of disease progression in neurodegenerative disorders may enable early 
intervention before clinical manifestation of a disease, which is crucial since early intervention at 
the premanifest stage is expected to be more effective. Neuroimaging biomarkers are indicative of 
the underlying disease pathology and may be used to predict future disease occurrence at the 
premanifest stage. As observed in many pivotal studies, longitudinal measurements of clinical 
outcomes, such as motor or cognitive symptoms, often present nonlinear sigmoid shapes over 
time, where the inflection points of the trajectories mark a meaningful time in disease progression. 
Therefore, to identify neuroimaging biomarkers predicting disease progression, we propose a 
nonlinear mixed effects model based on a sigmoid function to predict longitudinal clinical 
outcomes, and associate a linear combination of neuroimaging biomarkers with subject-specific 
inflection points. Based on an expectation-maximization (EM) algorithm, we propose a method 
that can fit a nonlinear model with many potentially correlated biomarkers for random inflection 
points while achieving computational stability. Variable selection is introduced in the algorithm in 
order to identify important biomarkers of disease progression and to reduce prediction variability. 
We apply the proposed method to the data from the Predictors of Huntington’s Disease study to 
select brain subcortical regional volumes predictive of the inflection points of the motor and 
cognitive function trajectories. Our results reveal that brain atrophy in the striatum and expansion 
of the ventricular system are highly predictive of the inflection points. Furthermore, these 
inflection points may precede clinically defined disease onset by as early as a decade and thus may 
be useful biomarkers as early signs of Huntington’s Disease onset.
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For many neurological disorders, including Huntington’s disease (HD) and Alzheimer’s 
disease, no biomarker exists to objectively and fully determine disease onset age (Reilmann 
et al., 2014; Biglan et al., 2013). Thus, the clinically defined disease diagnosis for these 
disorders relies on measurements of clinical symptoms, which may not be present in patients 
in the early stages of disease. Because of this fact, recent efforts have focused on identifying 
association between temporal clinical measurements and biomarkers that may reflect the 
underlying disease pathology and progression, with the eventual goal of early intervention 
(Dubois et al., 2014). The existing literature suggests that longitudinal measurements of 
many clinical symptoms take a nonlinear sigmoid shape (Jedynak et al., 2012; Samtani et al., 
2012), in which there is an early phase of gradual change followed by a period of 
acceleration around the time of clinical diagnosis. For example, Paulsen et al. (2014) 
demonstrated that motor and cognitive outcomes of premanifest HD subjects showed a 
sigmoid degeneration shape over time. Nonlinear models have also been discussed by the 
European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as 
clinical trial design tools for studying neurodegenerative disorders (Romero et al., 2015).
Existing literature on modeling progression of neurodegenerative disorders mostly describes 
the population average trend, which does not associate model parameters with subject-
specific biomarkers, and thus limiting its applications for predicting progression in 
individuals. In practice, many biomarkers may be predictive of disease progression in 
individual subjects. For example, prognostic biomarkers, including neuroimaging measures, 
are suggested to be useful in predicting early motor or cognitive abnormalities in HD 
(Paulsen et al., 2014). Some of the most promising imaging biomarkers include volumetric 
measures derived from brain structural magnetic resonance imaging (MRI) (Paulsen et al., 
2014). An important goal of current research on HD is to identify potentially useful 
biomarkers to predict disease progression as measured by repeated clinical measurements 
over time, which typically follow a nonlinear trajectory. The ability to predict these 
nonlinear trajectories using prodromal biomarkers will enable early disease intervention and 
prevention.
In this paper, we develop methods to model nonlinear disease progression using a nonlinear 
mixed effects model (NLMEM) with random inflection points. We model the long-term 
trajectory using a sigmoid function indexed by four parameters, namely, the minimal value, 
range, disease progression rate, and inflection point for the rate of progression. The 
inflection point is then modeled as a linear function of the baseline biomarkers. The 
inflection point is particularly important as it marks the critical time of maximal rate of 
deterioration, after which the disease progression continues but no longer accelerates. With 
Alzheimer’s disease, empirical evidence shows that the acceleration of cognitive decline can 
begin months or even years before a clinical diagnosis is made (Amieva et al., 2005; Grober 
et al., 2008) and the inflection point where the rate of progression stops increasing may be a 
crucial landmark in disease abnormality (Jedynak et al., 2012). For HD, our preliminary 
analysis in Section 2 shows that these inflection points may occur earlier than clinical 
diagnosis and are correlated with diagnosis. Thus they may be used in clinical trial 
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recruitment to maximize the chance of observing a diagnosis during the trial and thus to 
improve the power.
The main contribution of our work is to propose a penalized NLMEM for identifying 
important biomarkers for disease progression characterized by the inflection points in the 
model. Although NLMEMs have been extensively studied in the literature (e.g., Lindstrom 
and Bates, 1990; Wolfinger, 1993; Davidian and Giltinan, 1995; Pinheiro and Bates, 1995, 
2000), existing methods are restricted to fitting models with a small number of covariates, 
and the computational convergence may strongly depend on the choice of initial values. For 
high-dimensional settings, although variable selection has been considered for linear mixed 
effects model (Bondell et al., 2010; Fan and Li, 2012), there is little work for NLMEMs. An 
exception is Ke and Wang (2001), who proposed a semiparametric nonlinear mixed effects 
model together with Laplace approximations to the marginal likelihood and penalized 
marginal likelihood for estimation. Wang and Leng (2012) proposed an unified method 
using least squares approximation to the marginal likelihood; Wierzbicki et al. (2014) 
adopted a sparse semiparametric nonlinear marginal model for chromatographic fingerprint 
data. However, the parameters subject to variable selection are for fixed effects, while in our 
case the parameters being selected are for random effects and thus will enter the covariance 
matrix in the marginal model, rendering the methods in Wang and Leng (2012) and 
Wierzbicki et al. (2014) non-applicable.
In this paper, we simultaneously account for multiple biomarkers predicting random 
inflection points via penalization and propose an expectation-maximization (EM) algorithm-
based approach for estimation, where initial values are chosen using a simple two-stage 
procedure. Due to the challenges in computing the integral over the random effects and 
optimizing the nonlinear objective function, directly fitting a nonlinear mixed effects model 
with a large number of predictors for the random effects leads to either unstable estimates or 
non-convergence, especially when the covariates for random effects may be correlated. To 
overcome these challenges, we transform a difficult nonlinear optimization with multivariate 
predictors to an easy problem of penalized least squares. Since the convergence of an 
NLMEM procedure relies heavily on the choice of initial values, we propose a simple and 
effective two-stage approach to obtain initial values. We show that the EM-algorithm based 
estimate is consistent and enjoys the oracle property for variable selection. We apply the 
method to our motivating example to identify biomarkers associated with inflection points 
and discuss implications on HD clinical trial planning.
2. The Motivating PREDICT-HD Study
HD is a monogenic disorder caused by the expansion of trinucleotide cytosine-adenine-
guanine (CAG) in the HTT gene (MacDonald et al., 1993). Subjects with an expanded CAG 
repeats (≥ 36) in the huntingtin gene will eventually develop HD, but age at HD onset is not 
fully determined by CAG expansion status. The PREDICT-HD study (Paulsen et al., 2008) 
is a 32-site observational study to better characterize the natural history of HD so that 
preventive intervention can be initiated at the best time to maximize success. The follow-up 
period for each individual was up to 10 years and annual or biennial measurements were 
taken for the variables in important domains of HD phenotypes including motor, cognitive 
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and behavioral symptoms. The PREDICT-HD data we analyzed include 1,222 subjects with 
278 subjects without CAG repeats expansion, 915 premanifest expanded subjects (CAG 
repeats≥ 36) without HD diagnosis at the baseline, and 29 patients clinically confirmed to 
have an HD diagnosis at the baseline.
Since the CAG repeats length is inversely correlated with the age at onset of HD (Langbehn 
et al., 2004), to obtain less heterogeneous subgroups, we divide the sample into five groups 
according to a subject’s CAG repeats length. Specifically, group 1 are non-expanded 
controls with CAG ≤ 35 who will not be affected by HD, and groups 2–5 are expanded 
subjects with CAG in [36, 40), [40, 42], (42, 46], and >46, respectively. The first two groups 
are well defined in the literature (Langbehn et al., 2004), i.e., non-expanded controls and 
mild penetrated subjects. The last three groups are defined based on the sample 50th, 90th 
quantiles of those with CAG≥40 (full penetration). Consequently, there are 278, 74, 456, 
352, and 62 subjects in groups 1–5, respectively. Sensitivity analyses using other values to 
divide groups are presented in Supplementary Materials. Three longitudinal clinical 
outcomes for disease progression are of interest including a motor sign outcome, the total 
motor score (TMS); and two cognitive outcomes, the Stroop Word Test and the Symbol 
Digit Modalities Test (SDMT) (Kremer et al., 1996). The TMS is a summary of impairments 
of motor functions in ocular pursuit, tongue, finger, hands, arms, gait and so on (Kremer et 
al., 1996). The Stroop Word Test and SDMT are used as tools for evaluating cognitive 
executive functions.
As a preliminary analysis to examine the temporal patterns of the three disease progression 
outcomes, we fit locally weighted scatterplot smoothing (LOWESS) curves and sigmoid 
models without using any imaging biomarkers. We plot in Figures 1 and Web-2 the 
estimated sigmoid curves (the bold solid lines) superimposed on nonparametric LOWESS 
curves and stratified by CAG groups. Here we modeled the log-transformed total motor 
score, i.e., log(TMS+1), instead of the original scale. For groups 2, 3, and 4, the sigmoid 
model fits show good approximations to the nonparametric LOWESS fits. Some deviations 
are observed in group 5, which may be due to fewer available subjects and thus the 
LOWESS fit is highly variable. Thus, empirical observations are consistent with suggestions 
in the existing clinical literature (Jedynak et al., 2012; Wang et al., 2014; Samtani et al., 
2012; Romero et al., 2015) that a sigmoid function is appropriate to model disease 
progression. Additionally, to study the relationship between the inflection points and clinical 
diagnosis, we use the vertical lines to indicate the average position of the inflection points 
obtained from each individual trajectories. The inflection point represents the age at 
maximal rate of deterioration. Since information on new HD diagnosis during the study is 
also available, we use bullet points in groups 2–5 to represent premanifest gene expanded 
subjects who did not have a clinical diagnosis but had HD gene mutation, diamond points 
for subjects who developed HD during the follow-up period, and star points for subject who 
developed HD before the baseline. The plots show a close inverse relationship between the 
inflection point lines and CAG repeats length, where a longer repeats (higher disease 
burden) is associated with an earlier inflection point. Figures 1 and Web-2 also show that the 
average inflection points appear to precede the average diagnosis age for those who 
developed HD during the follow-up (with an average diagnosis age of 47.0, SD=9.8). In this 
study, brain structural magnetic resonance imaging (MRI) volumetric measures were also 
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collected at baseline for 1,107 subjects. In Section 5, we further examine the relationship 
between individual inflection points, neuroimaging biomarkers, and the likelihood of 
developing HD.
3. Methodologies
3.1 NLMEM for disease progression
Let Yij be the longitudinal outcome (e.g., motor or cognitive outcomes in PREDICT-HD) 
measuring disease progression, and let Zij be the age for subject i at visit j for i = 1, …, n 
and j = 1, …, mi. Let Xi be a vector of p-dimensional neuroimaging biomarkers measured at 
baseline, among which are predictive of the subject-specific parameters. Based on the 
preliminary analysis from PREDICT-HD study (Section 2) and existing literature (Samtani 
et al., 2012; Wang et al., 2014), we specify each subject’s individual trajectory as a sigmoid 
function and allow its inflection point to vary with baseline biomarkers Xi. Specifically, we 
assume
(1)
Here, τi is a subject-specific random inflection point in the sigmoid trajectory, θ1 is the 
minimum value, θ2 is a scale parameter, θ3 is the average rate of change, θ4 is the 
population average inflection point, and νi1 is a random intercept for subject i and is allowed 
to be correlated with the random effect νi2 for the inflection point. Because the random 
inflection point depends on biomarkers Xi, the proposed model personalizes the disease 
degeneration trajectory according to each subject’s biomarkers and accounts for the residual 
variability across subjects via the random effects. The inflection point τi captures the age 
when the symptom acceleration changes sign, which is a potentially important landmark of 
the disease process. Our goals are: (1) to estimate the average rate of progression and other 
parameters; to identify which neuroimaging biomarkers in Xi are informative of inflection 
points; and to assess the effects of all biomarkers Xi as a whole. Specifically, the second goal 
relates to variable selection for τi, while the last goal concerns the inference of the estimated 
β or the test H0 : β = 0.
3.2 Algorithm for the penalized NLMEM and theoretical justification
Denote by γ all parameters (βT, θT, ξT)T, where θ = (θ1, θ2, θ3, θ4)T and ξ includes the 
parameters  and Σ r. Let Oi = (Xi, Zij, Yij, j = 1, …, mi) be the observed data and define bi 
= (νi1, τi − θ4) and
We propose the following EM algorithm by treating bi as missing data.
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Note that the complete log-likelihood of the full data is
To fit the model with a large number of predictors Xi and perform variable selection, one 
approach is to maximize the penalized log-likelihood for the observed data
where ϕλ (·) is a penalty function. However, direct maximization of the above penalized 
like-lihood is a highly nonlinear optimization problem and computationally challenging. 
Instead, we propose an EM algorithm for estimation that transforms variable selection for 
nonlinear models into a much easier optimization of penalized least squares.
Specifically, in the E-step, we compute the conditional expectation of the log-likelihood 
evaluated at the current estimate of the parameters γ with respect to bi given the observed 
data Oi. In the M-step we compute parameters γ by maximizing the expected log-likelihood 
in the previous E-step. After the E- and M-steps are iterated until convergence, we perform 
variable selection for the biomarkers using penalized generalized least squares. A major 
advantage of the EM algorithm is that the challenge presented by the large number of 
predictors Xi only appears in the generalized least squares estimation in the M-step, which is 
a much easier optimization problem. We give the details in the following steps.
Step 1 (EM algorithm). Treating bi as missing data, the E-step is to evaluate the posterior 
expectation of some function of bi given the observed data Oi = (Xi, Zij, Yij, j = 1, …, mi) as
where g is a generic function of bi, and Rij = Yij −f (Zij, bi; θ).This calculation can be carried 
out using numerical integration method such as adaptive Gaussian quadratures (Pinheiro and 
Bates, 1995). In the M-step, we update parameters θ using one-step Newton-Raphson 
algorithm
where ∇θ f = ∇θ f (Zij, bi; θ) and  are the first and second derivatives, 
respectively, of f with respect to θ, and l indexes iteration. We update  as
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and update β by minimizing
Under a special case when νi1 and νi2 are independent, we can update β by minimizing
since Ê[bi] = (Ê[ν1i], Ê[τi] − θ4)T. We further update Σ r from the residual summed squares
As a note, when the dimension of Xi is high, it may be more accurate to replace n by (n − p) 
in the above expression using a restricted maximum likelihood estimate, where p is the 
dimension of β.
Step 2 (variable selection). We perform variable selection after the EM algorithm converges. 
We apply the adaptive LASSO (Zou, 2006) to the following penalized generalized least 
squares
where p is the dimension of β, and ϕλj (|βj|) = λj|βj| is the adaptive LASSO penalty with λj = 
λ|β̂j|−1 and β̂j the estimator from step 1. Particularly, this variable selection is implemented 
using the R glmnet package (Friedman et al., 2009).
Step 3 (post-selection inference). We apply the EM procedure again but using the selected 
subset of Xi, say, . From the EM procedure, we can estimate the effect of  and its 
asymptotic covariance via the Louis formula (Louis, 1982). To apply it, we consider both the 
parameters of interest β, θ and the nuisance parameters ξ. The Louis formula (Louis, 1982) 
for the information calculation is given as
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The inverse of this information matrix gives the asymptotic covariance for γ̂.
Note the advantage of the proposed EM algorithm is that the challenge due to variable 
selection of Xi only appears in the penalized least squares estimation in Step 2, which is a 
much easier optimization problem. Thus, the algorithm avoids direct optimization of the 
penalized observed data likelihood for the proposed nonlinear models. In addition, the 
proposed method can be easily generalized to other nonlinear models, where subject-specific 
parameters bi depend on a large number of predictors.
Finally, as in all NLMEM procedures, initial values play a crucial role to ensure convergence 
to a global maximum. To improve the convergence property, we further propose the 
following simple two-stage approach to select the initial values in the algorithm: at stage 1, 
we first fit an NLMEM without the biomarkers Xi in order to obtain the subject-specific 
random effects as b̂i using the best linear unbiased estimator (BLUE); we then estimate β by 
the following penalized least square
(2)
where b̂i = (ν̂1i, τ̂i − θ4). In stage 2, we fit another NLMEM based on model (1) to estimate 
the other parameters by fixing β = β̂0. Essentially, a two-stage approach fits an NLMEM in 
the first stage, ignoring biomarkers Xi as predictors, and attempts to recover their effects 
using the predicted random effects. Such a procedure is easy to implement, but one can show 
that it leads to a biased estimate of β even when using a penalty function (e.g., adaptive 
LASSO, Zou, 2006) that guarantees consistency due to the shrinkage effect of the BLUE for 
bi in the first step (see Web Appendix A).
We justify the proposed algorithm by proving its asymptotic properties in Web Appendix A. 
Specifically, in Theorem 1 (see Web Appendix A), we show that for a sequence of λn 
satisfying the conditions given in the appendix, the proposed estimator for γ̂λn is -
consistent. Furthermore, βλ̂n has an oracle property that the non-zero component of β0 can 
be identified with probability tending to one and it is asymptotically normally distributed. 
The proof follows the same arguments given in Johnson et al. (2008) and Liu and Zeng 
(2013). We provide a sketch of the proof in the Appendix. Finally, from the oracle property 
and the asymptotic normality in Theorem 1, it is clear that the estimator obtained in the post-
variable selection Step 3 should also be asymptotically normal.
To predict inflection points for new patients, two methods can be considered. 1) Include the 
outcomes Yi0 observed at the baseline from the new subjects to re-fit the NLME, and use the 
posterior mean of the inflection point, E(τi|Yi0, Xi, Zi), as the predicted inflection point; 2) a 
more computationally efficient way is to use the fixed effects, , as the predicted 
inflection point.
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We performed simulation studies to investigate the performance of the following methods: 
(1) the proposed EM algorithm-based NLME with/without adaptive LASSO penalty 
(NLME-EM ALASSO/NLME-EM); (2) the two-stage nonlinear mixed effects model with 
adaptive LASSO penalty (NLME-2 ALASSO); and (3) NLMEM assuming known 
informative biomarkers (NLME-T) with the LME approximation algorithm implemented in 
the R pack-age nlme. For a fair comparison, we also include a third step in the two-stage 
method similar as the Step 3 of NLME-EM. We evaluated three properties: 1) the estimation 
accuracy of the population-level parameters and individual inflection points; 2) the variable 
selection performance of the penalized procedure for choosing informative neuroimaging 
variables; and 3) the type I error rate and power of the test for detecting the overall effect of 
the neuroimaging variables.
We generated Xi from N (0, Ω), where p = 30 or p = 100, and Ω has either a compound 
symmetric structure with between-marker correlation of ρ = 0.1 or 0.3 or an autoregressive 
correlation structure with ρ = 0 7. The baseline age Zi1 was generated from N (40, 62). The 
individual inflection point τi given the biomarkers Xi was generated from 
, where (β1, β2, β3, …, β30)=(2, −1.5, 0, …, 0), and ,2, or 3. 
Finally, the longitudinal outcomes Yij were generated from the following sigmoid model
where σε = 10, (θ1, θ2, θ3, θ4) = (0, 100, 0.2, 45), and νi1 is independent of τi. In the 
simulation study, we considered the number of subjects to be n = 300 and the number of the 
observations per subject to be m = 3, 4, or 5.
Tables 1, Web-1, and 2 summarize the results for parameter estimation and variable selection 
properties using 200 replications. Table 1 shows that the mean absolute errors (MAE) of the 
estimated shape parameters (θ̂1, θ̂2, θ̂3, θ̂4) are slightly higher for NLME-2 ALASSO 
compared to NLME-EM ALASSO. Moreover, MAE of the estimated coefficients of the 
biomarkers (e.g., β̂) are larger for the NLME-2 ALASSO compared to NLME-EM 
ALASSO, especially when the variance of the random inection points is large.
To evaluate the accuracy of the estimated individual inflection points, in Table Web-1, we 
report the mean absolute error (MAE) and correlation (COR) between the estimated 
inflection point τ̂i and the true τi. Table Web-1 gives the results based on NLME-2, NLME-2 
ALASSO, NLME-EM, NLME-EM ALASSO methods, as well as NLME-T. From this table, 
we observe that the MAEs of NLME-EM ALASSO are lower than those of NLME-2 
ALASSO, while the correlations with the true τi of the former are higher. We also see that 
the MAEs of NLME-EM ALASSO are lower than those of NLME-EM. Thus through 
variable selection the estimation accuracy for the inflection point is improved. NLME-EM 
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ALASSO is comparable to NLME-T, which incorporates the known informative biomarkers 
in the model.
In terms of variable selection, in Table 2, we compare the number of correctly and 
incorrectly selected non-null variables and the proportion of over-fit, correct-fit, and under-
fit models. Both NLME-EM ALASSO and NLME-2 ALASSO appropriately select the 
informative biomarkers with large numbers of observations for each subject and moderate 
variability of τi. However, when  increases and the data are sparse (m = 3, 4), NLME-EM 
ALASSO outperforms NLME-2 ALASSO with a higher percentage of correct-fit and a 
lower percentage of under-fit models.
Finally, we investigated the performance of the Wald test based on NLME-EM and the F -
test based on the first-step of NLME-2 without variable selection for the overall effect of the 
biomarkers. The type I error rate was obtained under β = 0, and the power was obtained 
under (β1, β2, β3, …, β30) = δ * (2, − 1.5, 0, …, 0), where δ = 0.1, 0.2, 0.3, 0.4, or 0.5. The 
other settings were the same as in the previous simulations. The type I error rate was 
computed using 1000 simulations, and the power was computed using 400 simulations. The 
estimated type I error rates for the F -test are 0.057 and 0.056 for the two cases, respectively, 
which are close to the nominal level of 0.05. Figure Web-1 summarizes the power as a 
function of δ. We obverse that both tests show reasonable power for detecting the effect of 
the biomarkers under the alternative hypothesis, and NLME-EM-based Wald test is more 
powerful than NLME-2-based F -test. A possible reason for this finding is that because of 
the shrinkage effect of BLUE for bî, the first-step of NLME-2 underestimates β, and 
therefore, the power of the F -test is lower compared to NLME-EM, which is a consistent 
approach. We thus demonstrate that the proposed NLME-EM provides much greater power 
than NLME-2 for detecting biomarker effects.
5. Application to PREDICT-HD Study
We applied the proposed methods to the PREDICT-HD study introduced in Section 2. In 
PREDICT-HD, the regional and global measures of volumes at cortical and subcortical 
regions of interest (ROIs) were obtained in neuroanatomical atlas, after preprocessing 
structural MRIs using Freesurfer 5.2 (http://surfer.nmr.mgh.harvard.edu; see, Paulsen et al., 
2014). Previous clinical evidence (Paulsen et al., 2014) indicated a strong association 
between some of these biomarkers and HD age-at-onset. Furthermore, it has been shown 
that atrophy in the stratium and expansion of the lateral ventricles may manifest as early as 
11 years before the estimated onset of HD (Walker, 2007). However, no work has been done 
to select which biomarkers are most predictive of the disease progression as measured by 
motor or cognitive outcomes in multivariate models, which is the main goal of this work.
First, we fit the sigmoid NLMEM without using the structural MRI regional brain volumes 
from a joint NLME model (Web-1) of three outcomes reflecting motor and cognitive 
impairment of HD. Because we are interested in disease progression, we fit separate models 
for the non-expanded control subjects (the first group in Figures 1 and Web-2) and the 
expanded subjects who carry the HD mutation. Figures 1 and Web-2 show the estimated 
sigmoid curves stratified by the CAG group for the log-transformed total motor score (TMS) 
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and two cognitive outcomes (Stroop Word Test and SDMT). The sigmoidal model fits data 
adequately as shown in the residual plots in Figure Web-3 and goodness-of-fit test. To check 
the independence assumption, we computed the within subject one-lag correlations of the 
errors which showed negligible correlations −0.08, −0.15, and −0.15 for TMS, Stroop Word 
and SDMT, respectively.
Table 3 summarizes the estimated progression rates and the average inflection points. 
Interestingly, we see a monotone relationship between the average inflection points and the 
CAG group. Specifically, the mean inflection points are around 60, 50, 40, and 30 years of 
age, respectively, for the four CAG groups. Groups with higher CAG repeats length have 
earlier inflection points (i.e., the curve is shifted to the left), indicating earlier disease 
acceleration and faster disease progression. The magnitude of the rate of change (parameter 
θ3) also increases with CAG repeats length. These results are consistent with the literature 
that the CAG repeats length is inversely correlated with the age at onset of HD (Langbehn et 
al., 2004) and positively correlated with disease burden (Langbehn et al., 2010). For subjects 
in group 2, cognitive decline is similar to that in the normal aging group 1 (see Figures 1 and 
Web-2). The last column of Table 3 presents the p-values for detecting difference in the 
inflection point between the three outcomes. In Group 3, the average inflection points differ 
significantly for the three outcomes, with Stroop Word Test showing the earliest sign of 
decline compared to TMS and SDMT (i.e., about 4.5 and 6.1 years earlier than TMS and 
SDMT, respectively). For the other three groups, the inflection points for the three outcomes 
are not significantly different.
Next, we considered the following model to incorporate the structural MRI biomarkers and 
applied the proposed NLME-EM with adaptive lasso penalty to cope with correlated brain 
regional volumes in the variable selection. For a subject in the gth group (g = 2, …, 5),
(3)
where (θ1g, θ2g, θ3g, θ4g) are the sigmoid parameters for the gth group, and Xi is the 
baseline neuroimaging biomarkers as listed in Table Web-3. The regional volumes were first 
normalized by dividing by the total intracranial volume (ICV) and then standardized by 
subtracting the mean and dividing by the standard deviation of MRI regional volumes for the 
controls. We tested the overall effects of the 39 normalized regional volumes using the F -
test based on the first step of the NLME-2 and the Wald test based on the NLME-EM. The 
p-values for all three outcomes are less than 10−15; thus, the neuroimaging variables have 
significant effects on predicting the inflection points for the three outcomes. The updated 
inflection points after including neuroimaging biomarkers are in general earlier than without 
using these markers (Table 3, footnotes), demonstrating the utility of using them as 
prodromal markers to identify subjects with earlier inflection points.
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The coefficients for the selected brain regions are listed in Table Web-3, which can be 
interpreted as a shift in the inflection point due to 1 standard deviation change in the regional 
volumes. For example, 0.1 standard deviation unit atrophy in the right pallidum area is 
associated with about 4.5 months (0.37 years) earlier inflection point for the TMS. 
Additionally, Figure 2 shows three representative slices for part of the selected regions of 
interest (ROIs) coefficients for the TMS. Note that we did not assume that the left and right 
brain ROIs are symmetric. Although the left and right brain ROIs are highly correlated, they 
do not have exactly the same effect. Overall, we see that atrophy in subcortical regions and 
expansion of the ventricle system and vessel predict the inflection points. Different ROIs 
tend to predict inflection points for motor and cognitive outcomes, suggesting distinct 
underlying pathology for the two clinical domains of HD.
From Table Web-3, we see that the penalized NLME-EM selected subcortical ROIs left and 
right pallidum, left amygdala, right putamen, and CC-Mid-posterior as predictors of the 
inflection point for motor function. Right thalamus and right hippocampus were also 
selected, but with negative coefficients due to their strong correlation with other selected 
ROIs (the correlation values ρ range from 0.53 to 0.66). Pallidum, putamen and thalamus 
belong to the basal ganglia system, with their primary function as to control and regulate 
activities of the motor and premotor cortical areas so that voluntary movements can be 
performed smoothly (Chakravarthy et al., 2010). Additionally, the 3rd ventricle, optic 
chiasm, right vessel, right choroid plexus are also selected, and all show considerable 
expansion. This may be because that the intracranial volume is less likely to change, space 
from the lost cortical and subcortical volumes may be filling with fluid to maintain the 
overall structural integrity of the organ (Seidler et al., 2010).
For the cognitive outcome, Stroop Word Test, penalized NLME-EM chooses the subcortical 
ROIs right pallidum, left amygdala, and left cerebellum white matter. The ROIs right 
amygdala, brain stem, CC-central and CC-Anterior are also chosen, but with negative 
coefficients due to high correlations with other selected ROIs (the correlation values range 
from 0.4 to 0.67). CC stands for Corpus Callosum, which is the largest white matter that 
connects the left and right cerebral hemispheres to enable interhemispheric communication. 
Cerebellum plays an important role in motor control and is involved in some cognitive 
functions such as attention and language. For the cognitive measure SDMT, slightly different 
ROIs were chosen. The expansion of the ventricle system and vessel also significantly 
predict the inflection point for both the Stroop Word Test and SDMT.
To evaluate the predictive performance of the estimated inflection points, we computed their 
correlation with the observed age at onset of HD and lead time (the difference between the 
age at onset of HD and the inflection point). Group 5 with the highest CAG repeats tends to 
show the earliest inflection points. The correlations between the inflection points and age at 
onset of HD are 0.49 (95% bootstrap CI [0.32, 0.65]) for TMS, 0.45 (95% bootstrap CI 
[0.28, 0.60]) for Stroop Word, and 0.42 (95% bootstrap CI [0.27, 0.58]) for SDMT. The 
associations are shown in Figure 3. It can be seen that the majority of subjects with clinically 
confirmed HD during the follow-up period have positive lead times, and thus they manifest 
early signs of degeneration in the brain. The inflection points predicted from the 
neuroimaging biomarkers are much earlier than clinically defined HD onset, with mean lead 
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times of 8.8, 9.5, and 10.4 years for TMS, Stroop word test, and SDMT, respectively. Thus, 
neuroimaging measures are useful biomarkers for identifying subjects with earlier disease 
progression. Due to biological variation and measurement errors, the estimated inflection 
points may not be uniformly earlier than the diagnosis age in all subjects. Subjects with 
negative lead times tend to have early HD onset (≤50) but shorter instead of longer CAG 
repeats length. Thus, these patients may have a slightly different pathology than a typical 
patient and other prognostic factors not captured in brain atrophy measures may have 
contributed to disease progression. In addition, we used the Cox model to check the overall 
prediction performance. Figure Web-4 in the Supplementary Materials shows a negative 
association between the hazard rate of HD onset and the neuroimaging scores.
Lastly, in Figure Web-5, we superimposed fit individual sigmoid trajectories from six 
subjects on their observed measurements of the TMS. The six subjects are from groups 3, 4, 
and 5, respectively. The vertical dotted lines correspond to the individual inflection points. 
The first red dot of each subject corresponds to his/her age when HD was clinically 
diagnosed. We observe that the sigmoid trajectories fit the observed individual trends 
adequately, and the inflection point tends to be earlier than the age at diagnosis of HD.
6. Discussion
In this work, we propose NLMEMs for inferring subject-specific random inflection points as 
measures of disease progression. To incorporate many potentially correlated neuroimaging 
biomarkers, we developed an EM algorithm-based approach to overcome the computational 
challenges, stabilize estimation, and achieve variable selection. The proposed method 
simultaneously select the informative neuroimaging biomarkers and estimate individual 
inflection points based on the NLMEM. In our method, variable selection reduces to a 
penalized least squares form, which has a clear computational advantage. A simple two-
stage approach is proposed to provide initial values for the EM algorithm, which reduces the 
number of iterations and improves computational convergence rate and performance of the 
algorithm. We apply the proposed methods to the PREDICT-HD study, and find that the 
inflection points tend to occur earlier than the age of HD onset defined clinically (mainly 
based on the motor impairment symptoms). Moreover, the use of MRI imaging biomarkers 
as predictors of individualized inflection point allows obtaining earlier detection of 
inflection points in subjects not yet diagnosed with HD.
Here, the effect of the structural variation in the HTT gene was modeled by stratification 
according to the CAG repeats length. An interesting future extension is to replace the 
stratification by a nonparametric piecewise linear or piecewise constant model. Another 
extension is to introduce different sparseness for neuroimaging variable effects β(CAG) in 
different CAG stratification groups and perform group-LASSO for variable selection. A 
more flexible model will allow parameters in the nonlinear function to depend on subject-
specific covariates, but may be more computationally challenging. Lastly, although our 
method is presented for sigmoid nonlinear function, which was motivated by the PREDICT-
HD study data, it is not restricted to sigmoid nonlinear function. Other nonlinear models can 
be considered under the proposed framework.
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Descriptive plots of logarithm of motor (TMS) and cognitive outcome (Stroop Word) over 
age for subjects in the PREDICT-HD study. Bullet points in groups 2–5 represent 
premanifest gene expanded subjects who did not have a clinical diagnosis, diamond points 
represent subjects who developed HD during the follow-up period, and star points represent 
subject who developed HD before the baseline. The plot shows a close inverse relationship 
between the inection point lines and CAG repeats length, where a longer repeats (higher 
disease burden) associated with an earlier inection point. This figure appears in color in the 
electronic version of this article.
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Three representative slices for coefficients of part of the selected ROIs for predicting the 
inection point for the total motor scores. The MNI coordinates are x = 0, y = 2, z = −7. The 
green and red ROIs correspond to the left and right Pallidum; the blue ROI is the right 
Thalamus Proper, the yellow ROI is the right Putamen; and the dark blue ROI is the right 
choroid plexus.
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Association between lead time and age at onset of HD. Lead time is computed as observed 
age of HD onset minus inection points for total motor score (Top Left), stroop word test 
(Top Right), or SDMT (Bottom). This figure appears in color in the electronic version of this 
article.
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